Literature DB >> 17257465

Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003-2004.

Rajender R Aparasu1, Vinod Bhatara.   

Abstract

OBJECTIVES: This study examined patterns and determinants of antipsychotic prescribing in children and adolescents receiving outpatient care in the United States.
METHODS: Antipsychotic prescribing practices for patients younger than 20 years were examined using the 2003-2004 National Ambulatory Medical Care Survey and the outpatient department portion of the 2003-2004 National Hospital Ambulatory Medical Care Survey. The analysis focused on outpatient visits involving 11 typical and six atypical antipsychotic agents. National visit estimates were used to characterize the nature and extent of antipsychotic prescribing for patients younger than 20 years. Multiple logistic regression analysis was applied to visits involving children and adolescents to examine the need, predisposing, and enabling factors associated with antipsychotic prescribing.
RESULTS: Antipsychotic medications were prescribed in two million outpatient visits annually involving children and adolescents, representing 1% of overall visits by children and adolescents in 2003-2004. Most (99%) of these visits involved prescribing of atypical agents. The most frequently prescribed atypical agents were risperidone, quetiapine, and aripiprazole. The majority of the visits involving antipsychotic medications in children were seen in patients over 9 years, males, and whites. Factors positively associated with antipsychotic prescribing in children and adolescents included age over 9 years, diagnoses (bipolar disorder, psychoses, depression, disruptive behavior, and anxiety), and visits to specialists. Private insurance was negatively associated with antipsychotic prescribing.
CONCLUSIONS: Although the findings were based on cross-sectional analyses of outpatient visit data, the study revealed that atypical antipsychotic medications are being commonly and extensively prescribed to children and adolescents despite the relatively limited scientific evidence to support their pediatric use. Well-designed studies are urgently needed in children and adolescents to address atypical antipsychotic use for a variety of psychiatric disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17257465     DOI: 10.1185/030079906X158075

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  16 in total

1.  Medication use and spending trends among children with ADHD in Florida's Medicaid program, 1996-2005.

Authors:  Catherine A Fullerton; Arnold M Epstein; Richard G Frank; Sharon-Lise T Normand; Christina X Fu; Thomas G McGuire
Journal:  Psychiatr Serv       Date:  2012-02-01       Impact factor: 3.084

2.  Atypical antipsychotic medication in preschool children.

Authors:  Joachim F Hallmayer
Journal:  Curr Psychiatry Rep       Date:  2007-06       Impact factor: 5.285

3.  Trends, correlates, and disease patterns of antipsychotic use among children and adolescents in Taiwan.

Authors:  Yuan-Chang Hsu; I-Chia Chien; Happy Kuy-Lok Tan; Ching-Heng Lin; Shu-Wen Cheng; Yiing-Jenq Chou; Pesus Chou
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2013-05-08       Impact factor: 4.328

4.  Adolescent olanzapine sensitization is correlated with hippocampal stem cell proliferation in a maternal immune activation rat model of schizophrenia.

Authors:  Shinnyi Chou; Sean Jones; Ming Li
Journal:  Brain Res       Date:  2015-06-03       Impact factor: 3.252

5.  Antipsychotic use varies by patient age.

Authors:  Elisa F Cascade; Amir H Kalali; Leslie Citrome
Journal:  Psychiatry (Edgmont)       Date:  2007-07

6.  The effects of prior authorization policies on medicaid-enrolled children's use of antipsychotic medications: evidence from two mid-Atlantic states.

Authors:  Bradley D Stein; Emily Leckman-Westin; Edward Okeke; Deborah M Scharf; Mark Sorbero; Qingxian Chen; Ka Ho Brian Chor; Molly Finnerty; Jennifer P Wisdom
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-08-21       Impact factor: 2.576

7.  Antipsychotic prescription in children and adolescents: an analysis of data from a German statutory health insurance company from 2005 to 2012.

Authors:  Christian J Bachmann; Thomas Lempp; Gerd Glaeske; Falk Hoffmann
Journal:  Dtsch Arztebl Int       Date:  2014-01-17       Impact factor: 5.594

8.  Clinical characteristics of children receiving antipsychotic medication.

Authors:  Robert L Findling; Sarah McCue Horwitz; Boris Birmaher; Robert A Kowatch; Mary A Fristad; Eric A Youngstrom; Thomas W Frazier; David Axelson; Neal Ryan; Christine A Demeter; Judith Depew; Benjamin Fields; Mary Kay Gill; Elizabeth A Deyling; Brieana M Rowles; L Eugene Arnold
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-08       Impact factor: 2.576

Review 9.  The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity.

Authors:  C Cuerda; C Velasco; J Merchán-Naranjo; P García-Peris; C Arango
Journal:  Eur J Clin Nutr       Date:  2013-12-11       Impact factor: 4.016

10.  Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients.

Authors:  Ann E Maloney; Linmarie Sikich
Journal:  Neuropsychiatr Dis Treat       Date:  2010-11-10       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.